Customised Peripheral Corneal Cross-linking (P-CXL) for Ultra-thin Corneas with Stage III and IV Keratoconus.

PURPOSE: This study aims to determine whether customised peripheral corneal cross-linking (P-CXL) can halt keratoconus progression in ultrathin corneas with stage 3 and 4 keratoconus, with thinnest pachymetry well below 400 μm and therefore excluded from most treatment protocols.

METHODS: This retrospective study included 21 eyes with progressive keratoconus and thinnest pachymetry ranging from 97 to 399 μm (mean 315 μm), who underwent P-CXL between 2007 and 2020. The procedure involved preoperative NSAIDs therapy, tomography-guided customized epithelial debridement, the use of both hypo-osmolar and iso-osmolar riboflavin solutions, and 9.0 mW/cm2 UV-A irradiation for 10 minutes. The outcome measures were best spectacle-corrected visual acuity (BSCVA), mean keratometry, maximum keratometry, and thinnest pachymetry.

RESULTS: After a minimum follow-up period of 12 months, P-CXL stabilized or improved mean keratometry and maximum keratometry in 85.7% of eyes (Kavg from 57.48 ± 9.38 to 56.43 ± 8.96 D, p < 0.001; Kmax from 72.77 ± 12.74 to 70.00 ± 11.50 D, p < 0.001), BSCVA in 90.5% of eyes (from 4.48 ± 2.85 to 5.72 ± 3.34 decimals, p < 0.001), and thinnest pachymetry in 81% of eyes (from 315.81 ± 90.05 to 342.33 ± 74.22 μm, p = 0.08). No adverse events and no loss of endothelial cell density occurred.

CONCLUSIONS: Customised peripheral corneal cross-linking (P-CXL) treated very severe keratoconus with a success rate of 85.7% and improved visual acuity and tomographic indicators in most cases. While a longer follow-up and a larger sample would help to support such conclusions to a greater extent, these results allow to broaden the treatment spectrum for patients with stage 3 and 4 keratoconus and contact lens tolerance.